68Ga标记FAPI二聚体的合成、临床前评价及初步临床PET显像研究
本研究基于喹啉类FAPI变体FAPI-46设计合成68Ga标记的FAPI二聚体68Ga-DOTA-2P(FAPI)2,在CAFs中检测结合特性,在FAP阳性PDX模型中进行小动物PET和生物分布实验,并在3名健康志愿者中评估有效剂量、在3例癌症患者中对比68Ga-FAPI-46与68Ga-DOTA-2P(FAPI)2的PET/CT显像。结果显示二聚体在PDX中肿瘤摄取约为68Ga-FAPI-46的2倍,患者所有肿瘤病灶SUVmax为8.1-39.0,高于68Ga-FAPI-46的1.7-24.0(P < 0.001),有效剂量为1.19E-02 mSv/MBq。
要点
- 68Ga-DOTA-2P(FAPI)2在PDX中肿瘤摄取约为68Ga-FAPI-46的2倍。
- 3例患者所有肿瘤病灶SUVmax为8.1-39.0,高于68Ga-FAPI-46的1.7-24.0(P < 0.001)。
- 68Ga-DOTA-2P(FAPI)2有效剂量为1.19E-02 mSv/MBq。
核心结论
- 68Ga-DOTA-2P(FAPI)2较68Ga-FAPI-46具有更高的肿瘤摄取和滞留特性,有望成为FAP阳性恶性肿瘤诊断显像和靶向治疗的示踪剂。
研究设计与样本
- 基于喹啉类FAPI变体FAPI-46合成68Ga-DOTA-2P(FAPI)2,在CAFs中检测结合特性。
- 在FAP阳性PDX模型中使用小动物PET和生物分布实验测定临床前药代动力学。
- 在3名健康志愿者中评估68Ga-DOTA-2P(FAPI)2有效剂量,并在3例癌症患者中对比68Ga-FAPI-46与68Ga-DOTA-2P(FAPI)2的PET/CT显像。
主要发现
- 68Ga-DOTA-2P(FAPI)2在磷酸盐缓冲液和胎牛血清中4 h内稳定。
- FAPI二聚体在体外和体内对FAP显示高亲和力和特异性。
- 68Ga-DOTA-2P(FAPI)2在PDX中的肿瘤摄取约为68Ga-FAPI-46的2倍,而健康器官示踪剂摄取低且体清除快。
- 3例癌症患者PET/CT扫描显示所有肿瘤病灶中68Ga-DOTA-2P(FAPI)2的瘤内摄取高于68Ga-FAPI-46(SUVmax分别为8.1-39.0 vs. 1.7-24.0;P < 0.001)。
关键数值与推荐
- 68Ga-DOTA-2P(FAPI)2的有效剂量为1.19E-02 mSv/MBq,使用OLINDA计算。
- 患者肿瘤病灶SUVmax:68Ga-DOTA-2P(FAPI)2为8.1-39.0,68Ga-FAPI-46为1.7-24.0,P < 0.001。
临床怎么用
- 68Ga-DOTA-2P(FAPI)2可能作为FAP阳性恶性肿瘤的诊断显像示踪剂,并具备靶向治疗的潜在应用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer-associated fibroblasts (CAFs) are crucial components of the tumor microenvironment. Fibroblast activation protein (FAP) is overexpressed in CAFs. FAP-targeted molecular imaging agents, including the FAP inhibitors (FAPIs) 04 and 46, have shown promising results in tumor diagnosis. However, these molecules have a relatively short tumor-retention time for peptide-targeted radionuclide therapy applications. We aimed to design a 68Ga-labeled FAPI dimer, 68Ga-DOTA-2P(FAPI)2, to optimize the pharmacokinetics and evaluate whether this form is more effective than its monomeric analogs. Methods:68Ga-DOTA-2P(FAPI)2 was synthesized on the basis of the quinoline-based FAPI variant (FAPI-46), and its binding properties were assayed in CAFs. Preclinical pharmacokinetics were determined in FAP-positive patient-derived xenografts using small-animal PET and biodistribution experiments. The effective dosimetry of 68Ga-DOTA-2P(FAPI)2 was evaluated in 3 healthy volunteers, and PET/CT imaging of 68Ga-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 was performed on 3 cancer patients. Results:68Ga-DOTA-2P(FAPI)2 was stable in phosphate-buffered saline and fetal bovine serum for 4 h. The FAPI dimer showed high affinity and specificity for FAP in vitro and in vivo. The tumor uptake of 68Ga-DOTA-2P(FAPI)2 was approximately 2-fold stronger than that of 68Ga-FAPI-46 in patient-derived xenografts, whereas healthy organs showed low tracer uptake and fast body clearance. The effective dose of 68Ga-DOTA-2P(FAPI)2 was 1.19E-02 mSv/MBq, calculated using OLINDA. Finally, the PET/CT scans of the 3 cancer patients revealed higher intratumoral uptake of 68Ga-DOTA-2P(FAPI)2 than of 68Ga-FAPI-46 in all tumor lesions (SUVmax, 8.1-39.0 vs. 1.7-24.0, respectively; P < 0.001). Conclusion:68Ga-DOTA-2P(FAPI)2 has increased tumor uptake and retention properties compared with 68Ga-FAPI-46, and it could be a promising tracer for both diagnostic imaging and targeted therapy of malignant tumors with positive expression of FAP.
引用
- Zhao L, Niu B, Fang J, et al. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer. J Nucl Med. 2021. PMID: 34556528. doi:10.2967/jnumed.121.263016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。